SINTX Technologies (SINTX Technologies) EBIT : $-8.85 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies EBIT?

SINTX Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.88 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.85 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SINTX Technologies's annualized ROC % for the quarter that ended in Mar. 2024 was -114.46%. SINTX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -39.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SINTX Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -340.78%.

SINTX Technologies EBIT Historical Data

The historical data trend for SINTX Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SINTX Technologies EBIT Chart

SINTX Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-4.79

-7.03

-9.28

-12.02

-8.26

SINTX Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-0.29	-2.46	-3.19	-2.32	-0.88

Competitive Comparison of SINTX Technologies's EBIT

For the Medical Devices subindustry, SINTX Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SINTX Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SINTX Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SINTX Technologies's EV-to-EBIT falls into.

SINTX Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.85 Mil.

SINTX Technologies (NAS:SINT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SINTX Technologies's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-12.788 * ( 1 - 0% )	/	( (10.699	+	11.646)	/ 2 )
=	-12.788	/	11.1725
=	-114.46 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.365	-	2.04	-	( 3.34	-	max(0, 2.906	-	5.532	+	3.34	))
=	10.699

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.561	-	2.489	-	( 5.762	-	max(0, 4.088	-	7.514	+	5.762	))
=	11.646

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

SINTX Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-3.536	/	( ( (8.92 + max(-0.156, 0))	+	(9 + max(-1.585, 0)) )	/	2 )
=	-3.536	/	( ( 8.92	+	9 )	/	2 )
=	-3.536	/	8.96
=	-39.46 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.685	+	0.888	+	0.619)	-	(2.04	+	0	+	0.308)
=	-0.156

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.483	+	0.707	+	0.562)	-	(2.489	+	0	+	0.848)
=	-1.585

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SINTX Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-8.85	/	2.597
	=	-340.78 %

SINTX Technologies EBIT Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

SINTX Technologies (SINTX Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

111A:Germany 111A:Germany

Address

1885 West 2100 South, Salt Lake City, UT, USA, 84119

Website

https://www.sintx.com

SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty.

Executives

David W. Truetzel	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien	officer: Chief Operating Officer	1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi	officer: VP Finance	C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin	officer: Vice President, Finance	C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros	officer: See Remarks	C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke	10 percent owner	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes	director, officer: Chief Fnancial Officer
Vytas Rupinskas	officer: SVP, Marketing	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson	director, officer: President and CEO	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham	officer: SVP, Global Sales	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield	officer: Chief Commercial Officer	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis	officer: Chief Operating Officer	9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119